WHO , 2019. World Malaria Report 2019 .Geneva, Switzerland: World Health Organization. Available at: https://www.who.int/publications/i/item/world-malaria-report-2019. Accessed November 11, 2020.
WHO , 2012. Updated WHO Policy Recommendation: Single Dose Primaquine as a Gametocytocide in Plasmodium Falciparum Malaria. Geneva, Switzerland: World Health Organization. Available at: https://www.who.int/malaria/publications/atoz/who_pq_policy_recommendation/en/. Accessed November 11, 2020.
WHO , 2015. Guidelines for the Treatment of Malaria, 3rd edition. Geneva, Switzerland: World Health Organization. Available at: https://www.who.int/malaria/publications/atoz/9789241549127/en/. Accessed November 11, 2020.
WHO , 2016. Testing for G6PD deficiency for safe use of primaquine in radical cure of P. vivax and P. ovale malaria. Geneva, Switzerland: World Health Organization. Available at: https://www.who.int/malaria/publications/atoz/g6pd-testing-pq-radical-cure-vivax/en/. Accessed November 11, 2020.
Howes RE , Battle KE , Satyagraha AW , Baird JK , Hay SI , 2013. G6PD deficiency. Global distribution, genetic variants and primaquine therapy. Adv Parasitol 81: 133–201.
Mbanefo EC et al. 2017. Association of glucose-6-phosphate dehydrogenase deficiency and malaria: a systematic review and meta-analysis. Sci Rep 7: 1–10.
Cappellini M , Fiorelli G , 2008. Glucose-6-phosphate dehydrogenase deficiency. Lancet 371: 64–74.
WHO , 2015. Policy Brief on Single-Dose Primaquine as a Gametocytocide in Plasmodium Falciparum Malaria. Geneva, Switzerland: World Health Organization. Available at: https://www.who.int/malaria/publications/atoz/policy-brief-single-dose-primaquine-pf/en/. Accessed November 11, 2020.
Howes RE et al. 2012. G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map. PLoS Med 9: e1001339.
Kent RJ , Thuma PE , Mharakurwa S , Norris DE , 2007. Seasonality, blood feeding behavior, and transmission of Plasmodium falciparum by Anopheles arabiensis after an extended drought in southern Zambia. Am J Trop Med Hyg 76: 267–274.
Stevenson JC , Norris DE , 2017. Implicating cryptic and novel anophelines as malaria vectors in Africa. Insects 8: 1–18.
Moss WJ , Hamapumbu H , Kobayashi T , Shields T , Kamanga A , Clennon J , Mharakurwa S , Thuma PE , Glass G , 2011. Use of remote sensing to identify spatial risk factors for malaria in a region of declining transmission: a cross-sectional and longitudinal community survey. Malar J 10: 163.
Deutsch-feldman M et al. 2018. Efficiency of a malaria reactive test-and-treat program in southern Zambia: a prospective, observational study. Am J Trop Med Hyg 98: 1382–1388.
Fanello CI , Karema C , Avellino P , Bancone G , Uwimana A , Lee SJ , d’Alessandro U , Modiano D , 2008. High risk of severe anaemia after chlorproguanil-dapsone+artesunate antimalarial treatment in patients with G6PD (A-) deficiency. PLoS One 3: e4031.
Kobayashi T , Kanyangarara M , Laban NM , Phiri M , Hamapumbu H , Searle KM , Stevenson JC , Thuma PE , Moss WJ , 2019. Characteristics of subpatent malaria in a pre-elimination setting in southern Zambia. Am J Trop Med Hyg 100: 280–286.
Mlambo G , Vasquez Y , Leblanc R , Sullivan D , Kumar N , 2008. Short report: a filter paper method for the detection of Plasmodium falciparum gametocytes by reverse transcription – polymerase chain reaction. Am J Trop Med Hyg 78: 114–116.
Bousema T , Drakeley C , 2011. Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination. Clin Microbiol Rev 24: 377–410.
Pinchoff J , Hamapumbu H , Kobayashi T , Simubali L , Stevenson JC , Norris DE , Colantuoni E , Thuma PE , Moss WJ , 2015. Factors associated with sustained use of long-lasting insecticide-treated nets following a reduction in malaria transmission in southern Zambia. Am J Trop Med Hyg. 93: 954–960.
PMI , 2020. US President’s Malaria Initiative Zambia: Malaria Operational Plan FY 2020. 2020: 1-136. Available at: https://www.pmi.gov/where-we-work/zambia. Accessed November 11, 2020.
Stuckey EM , Miller JM , Littrell M , Chitnis N , Steketee R , 2016. Operational strategies of anti-malarial drug campaigns for malaria elimination in Zambia’s southern province: a simulation study. Malar 15: 1–14.
|Past two years||Past Year||Past 30 Days|
|Full Text Views||654||253||1|
The WHO recommends single low-dose (SLD) primaquine as a gametocytocide to reduce Plasmodium falciparum transmission in areas of low transmission. Despite this recommendation, uptake of SLD primaquine has been low because of concerns of glucose-6-phosphate dehydrogenase (G6PD) deficiency. Individuals with G6PD deficiency can experience hemolysis when exposed to primaquine. In Southern Province, Zambia, malaria transmission has declined significantly over the past decade. Single low-dose primaquine may be an effective tool, but there is limited information on G6PD deficiency. We screened 137 residents in Macha, Southern Province, Zambia, and the prevalence of G6PD (A−) was 15%. We also revisited data collected from 2008 to 2013 in the same area and found the highest gametocyte burden among those aged 5–15 years. The findings from this study suggest that SLD primaquine targeted to school-aged children may be an effective tool to help achieve malaria elimination in southern Zambia.
The Southern and Central Africa International Centers of Excellence for Malaria Research includes the Biomedical Research and Training Institute, Zimbabwe; Johns Hopkins Malaria Research Institute, USA; Macha Research Trust, Zambia; National Institute of Health Research, Zimbabwe; Tropical Diseases Research Center, Zambia; University of the Witwatersrand, South Africa; and Université Protestante au Congo.
Financial support: This work was supported by the Johns Hopkins Malaria Research Institute, the Bloomberg Philanthropies, and the Division of Microbiology and Infectious Diseases, National Institutes of Allergies and Infectious Diseases, and National Institutes of Health as part of the International Centers of Excellence for Malaria Research (U19 AI089680).
Authors’ addresses: Tamaki Kobayashi, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, E-mail: email@example.com. Shaheen Kurani, Mayo Clinic, Health Sciences Research, Rochester, MN, and Mayo Clinic, Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Rochester, MN, E-mail: firstname.lastname@example.org. Harry Hamapumbu, Macha Research Trust, Choma, Zambia, E-mail: email@example.com. Jennifer C. Stevenson, Macha Research Trust, Choma, Zambia, and W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, E-mail: firstname.lastname@example.org. Philip E. Thuma, Macha Research Trust, Clinical Research Department, Choma, Zambia, and W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, E-mail: email@example.com. William J. Moss, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, and W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, E-mail: firstname.lastname@example.org.